Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Capital Expenditures (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Capital Expenditures for 12 consecutive years, with $17000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 183.33% to $17000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $103000.0 through Dec 2025, down 78.13% year-over-year, with the annual reading at $228000.0 for FY2025, 30.7% down from the prior year.
  • Capital Expenditures for Q4 2025 was $17000.0 at Aytu Biopharma, roughly flat from $17000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $329000.0 in Q2 2024, with the low at -$13.1 million in Q2 2021.
  • Average Capital Expenditures over 3 years is -$1.8 million, with a median of $17000.0 recorded in 2025.
  • The sharpest move saw Capital Expenditures tumbled 123.21% in 2021, then skyrocketed 183.33% in 2025.
  • Over 3 years, Capital Expenditures stood at -$13.1 million in 2021, then skyrocketed by 100.05% to $6000.0 in 2024, then surged by 183.33% to $17000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $17000.0, $17000.0, and $69000.0 for Q4 2025, Q2 2025, and Q1 2025 respectively.